Business Context and Reporting Period
This Form 8-K is filed by Bionomics Limited (not Neuphoria Therapeutics Inc.) on July 11, 2024. The registrant is an emerging growth company incorporated in Australia, with its American Depositary Shares (ADS) trading under the symbol BNOX on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material event is a notification from Nasdaq regarding a failure to meet the minimum bid price requirement:
- Deficiency: The closing bid price of the Company's ADS was below $1.00 per share for 30 consecutive business days between May 28, 2024, and July 10, 2024.
- Regulatory Action: The Company received a notice of delisting risk under Nasdaq Listing Rule 5450(a)(1).
- Current Status: The shares remain listed and traded on The Nasdaq Global Market pending compliance.
Guidance, Outlook, and Risks
Compliance Period: The Company has been granted an initial compliance period of 180 calendar days, ending on January 7, 2025.
Path to Compliance: To regain compliance, the Company must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.
Contingencies and Risks:
- If the Company fails to regain compliance by January 7, 2025, it may be eligible for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares) and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
- If the Company is unable to cure the deficiency or is ineligible for an additional period, Nasdaq will issue a notice that the shares will be subject to delisting.
Investor Verification Checklist
- Verify the current trading price of BNOX to assess the likelihood of meeting the $1.00 bid price requirement within the 180-day window.
- Monitor future announcements regarding the potential implementation of a reverse stock split.
- Review the Company's market capitalization and publicly held share value to determine eligibility for a second compliance period if the first is unsuccessful.
- Confirm the exact date of the next Nasdaq compliance deadline (January 7, 2025).